Skip to main content
. 2012 Mar;21(123):40–47. doi: 10.1183/09059180.00009011

Figure 1.

Figure 1.

Baseline New York Heart Association functional class (NYHA FC) predicts survival in patients with pulmonary hypertension using infused epoprostenol therapy. a) 162 patients followed for a median of 36 months. Reproduced from [5] with permission from the publisher. b) 178 patients followed for a median of 26 months. Reproduced from [6] with permission from the publisher.